Chronic kidney disease progresses silently. RenoraDx is developing approaches to detect earlier biological signals of kidney stress—at a stage when intervention may still be meaningful.
Illustrative only. Not based on clinical trial data.
Chronic kidney disease (CKD) is among the most prevalent non-communicable diseases globally, affecting an estimated 850 million people worldwide.1
Standard clinical markers—primarily serum creatinine and estimated glomerular filtration rate (eGFR)—lack sensitivity for early-stage injury. By the time these indicators fall outside normal range, substantial nephron loss may already have occurred.2
The majority of CKD cases go undiagnosed until late stages, limiting opportunities for meaningful clinical intervention.3
Kidney region highlighted for anatomical reference. Gold points indicate target signal detection area.
Emerging research suggests that kidney injury generates detectable molecular signals prior to the functional decline captured by GFR-based testing.4 Novel biomarkers—including urinary and plasma proteins associated with tubular stress and glomerular injury—have shown potential to identify CKD progression at earlier stages than conventional assays.5
The hypothesis that earlier detection translates to better outcomes is supported by clinical data in adjacent disease areas,6 and is an active area of investigation in nephrology.
Standard diagnostics are optimised for established disease, not early injury. This is the gap RenoraDx is working to address.
RenoraDx is developing a diagnostic approach aimed at identifying kidney stress earlier than conventional measures allow—without overstating what the science currently supports.
Targeting biological signals associated with early tubular and glomerular stress that precede measurable GFR decline. Grounded in published nephrology and proteomics research.
Translating biomarker candidates into a clinically actionable diagnostic format—designed with sensitivity for early-stage detection as the primary objective.
Pursuing rigorous validation through prospective cohort studies in collaboration with academic nephrology and clinical partners to establish diagnostic performance.
Initial focus on populations with known CKD risk factors—diabetes, hypertension, and cardiovascular disease—where earlier detection would have the greatest clinical value.
We are engaging with investors and research collaborators interested in advancing early detection in kidney disease. We welcome conversations from those working at the intersection of diagnostics, nephrology, and precision medicine.